TGFB1 and COVID-19: Thus, the identification of an overexpression of active TGF-β1 in survivors of COVID-19-ARDS 6-months after ICU discharge underscores its potential role in post-COVID fibrosis, especially in those displaying early signs of alveolar-capillary membrane thickening.